Impact of Right Ventricular Dysfunction and Tricuspid Regurgitation on Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement

Contemporary Trends in the Use and Outcomes of Surgical Treatment of Tricuspid Regurgitation

“…Most patients experiencing significant TR have concomitant valvular disease. Moderate‐to‐severe TR is present in 30% to 50% of patients with severe mitral regurgitation and in 12% to 25% of patients with severe aortic stenosis 4, 24, 25, 26, 27, 28. TR has been shown to be an independent negative predictor of long‐term survival among the following: (1) patients with multivalvular disease undergoing surgical or transcatheter aortic and mitral valve treatment,1, 2, 4, 25 (2) patients with heart failure who are treated medically,24, 29 and (3) patients with severe isolated TR who are treated medically 30, 31.…”

Comprehensive Right-Sided Assessment for Transcatheter Aortic Valve Replacement Risk Stratification: Time for a Change

“…39 retrospectively evaluated 519 patients treated with TAVR (access route, valve type, and procedural complications are not mentioned). They quantified RV systolic function, TR, and PH using 2D echocardiography at two time points (baseline and 6 months after TAVR).…”

“…The work by Schwartz et al 39 highlights the importance of considering TR severity in the context of other relevant comorbidities commonly seen in TAVR patients, in particular the presence of RV dysfunction, which might be the main driver of outcomes. It is important to highlight, however, that only 15 patients (3%) had severe TR, and the majority of patients had preserved RV systolic function at baseline.…”

“…Schwartz et al 39 should be commended for evaluating and quantitating these parameters before and after TAVR intervention. Their work certainly builds on the current evidence that RV function, rather than TR severity, dictates outcomes in TAVR patients.…”

Impact of concurrent tricuspid regurgitation on mortality after transcatheter aortic‐valve implantation

“…As expressed in Figure , our search identified 12 eligible studies enrolling a total of 41,485 TAVI patients (including a study by McCarthy et al enrolling 34,576 patients from the transcatheter valve therapy [TVT] registry, not but including a study by Arnold et al enrolling 21,661 patients from the TVT registry) (Table ). The study by Arnold et al from the TVT registry reported an adjusted OR for 30‐day mortality and the study by McCarthy et al from the TVT registry provided an unadjusted OR for in‐hospital mortality, thus the former was extracted and combined in a meta‐analysis for early mortality (Table ).…”